- Home
- NVS vs AZN Comparison
NVS vs AZN Comparison
Compare NVS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- AZN
- Stock Information
- Founded
- NVS 1895
- AZN 1992
- Country
- NVS Switzerland
- AZN United Kingdom
- Employees
- NVS N/A
- AZN N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- NVS Health Care
- AZN Health Care
- Exchange
- NVS Nasdaq
- AZN Nasdaq
- Market Cap
- NVS 254.8B
- AZN 255.5B
- IPO Year
- NVS 1991
- AZN 1993
- Fundamental
- Price
- NVS $126.71
- AZN $83.74
- Analyst Decision
- NVS Hold
- AZN Strong Buy
- Analyst Count
- NVS 5
- AZN 2
- Target Price
- NVS $119.00
- AZN N/A
- AVG Volume (30 Days)
- NVS 1.7M
- AZN 4.8M
- Earning Date
- NVS 10-28-2025
- AZN 11-06-2025
- Dividend Yield
- NVS 2.05%
- AZN 1.83%
- EPS Growth
- NVS N/A
- AZN 45.04
- EPS
- NVS 7.30
- AZN 6.02
- Revenue
- NVS $56,372,000,000.00
- AZN $58,127,000,000.00
- Revenue This Year
- NVS $9.44
- AZN $10.82
- Revenue Next Year
- NVS $2.65
- AZN $5.99
- P/E Ratio
- NVS $17.34
- AZN $13.92
- Revenue Growth
- NVS 12.88
- AZN 13.52
- 52 Week Low
- NVS $96.06
- AZN $61.24
- 52 Week High
- NVS $133.55
- AZN $86.57
- Technical
- Relative Strength Index (RSI)
- NVS 48.88
- AZN 56.49
- Support Level
- NVS $121.57
- AZN $80.48
- Resistance Level
- NVS $124.15
- AZN $84.22
- Average True Range (ATR)
- NVS 1.62
- AZN 1.28
- MACD
- NVS -0.49
- AZN -0.30
- Stochastic Oscillator
- NVS 47.77
- AZN 69.26
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.